PUBLISHER: The Business Research Company | PRODUCT CODE: 1713631
PUBLISHER: The Business Research Company | PRODUCT CODE: 1713631
Protein Degradation Therapy Global Market Report 2025
Protein degradation therapy is a treatment approach that focuses on the selective degradation of specific proteins within cells. This method employs small molecules, peptides, or other agents to induce the destruction of proteins that are either dysfunctional or contribute to disease. The objective is to reduce or eliminate harmful proteins associated with conditions such as cancer, neurodegenerative diseases, and autoimmune disorders.
Key products in protein degradation therapy include bavdegalutamide (ARV-110), vepdegestrant (ARV-471), among others. Bavdegalutamide, also known as ARV-110, is a novel therapy designed to target and degrade androgen receptors in prostate cancer cells. This therapy is utilized in fields such as oncology, neurodegenerative diseases, infectious diseases, and more, serving various end-users, including pharmaceutical companies, biotechnology firms, and academic and research institutions.
The protein degradation therapy market research report is one of a series of new reports from The Business Research Company that provides protein degradation therapy market statistics, including protein degradation therapy industry global market size, regional shares, competitors with a protein degradation therapy market share, detailed protein degradation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the protein degradation therapy industry. This protein degradation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The protein degradation therapy market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increase in prevalence of neurodegenerative diseases, increase in the success of targeted therapies, growth in investment in biotech innovation, rise in the need for personalized medicine, increase in the failure of conventional therapies to address certain diseases.
The protein degradation therapy market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing prevalence of chronic diseases, growing investment in biotech research, rising demand for targeted therapies, expansion of clinical trials, supportive regulatory environments. Major trends in the forecast period include development of next-generation PROTACs, integration of artificial intelligence and machine learning, emergence of combination therapies, development of personalized protein degradation therapies, and advancements in oral formulations and drug delivery systems.
The rising incidence of cancer is expected to drive the growth of the protein degradation therapy market. Cancer encompasses a variety of diseases characterized by uncontrolled cell proliferation and spread within the body. The increasing cancer rates are largely attributed to an aging population, along with lifestyle factors such as smoking, poor diet, insufficient physical activity, and growing obesity rates, which elevate the risk of various cancers. Protein degradation therapy is crucial in cancer treatment because it targets and removes specific proteins that support cancer growth and survival, potentially overcoming resistance to traditional therapies. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental agency, projected over 35 million new cancer cases by 2050, marking a 77% increase from the 20 million cases estimated in 2022. High human development index (HDI) countries are expected to see the greatest rise in new cases, with an additional 4.8 million cases predicted for 2050 compared to 2022 estimates. This increasing cancer burden is driving the growth of the protein degradation therapy market.
Key players in the protein degradation therapy market are forming strategic partnerships to develop innovative therapies, combine expertise, share resources, and accelerate the discovery and development of new drugs targeting disease-causing proteins. These partnerships leverage each company's strengths to achieve mutual benefits and success. For example, in June 2022, Merck KGaA, a Germany-based science and technology firm, entered into a multi-year research and licensing agreement with Proxygen, an Austria-based biotechnology company. Valued up to $2.55 billion, the partnership includes an upfront payment and potential milestone payments based on specific research, development, and commercial achievements. The collaboration aims to develop molecular glue degraders, leveraging Proxygen's expertise to reprogram cellular mechanisms for the selective elimination of disease-causing proteins, including those deemed "undruggable" by traditional methods.
In June 2024, Genexine, a South Korea-based biopharmaceutical company, merged with EPD Biotherapeutics for an undisclosed amount. This merger provides Genexine with essential talent and advanced technology, positioning it to lead in the global market. The integration of EPD Bio's bioPROTAC technology with Genexine's clinical and CMC development capabilities will facilitate the advancement of innovative new drugs. EPD Biotherapeutics, based in South Korea, specializes in the development of the protein degradation platform known as EPDeg.
Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc
North America was the largest region in the protein degradation therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the protein degradation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The protein degradation therapy market consists of revenues earned by entities by providing services such as drug discovery and development, target validation, preclinical and clinical testing and targeted protein degradation screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein degradation therapy market also includes sales of degraders, E3 ligase ligands, degron tags, biochemical assay kits and cellular assay kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Protein Degradation Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on protein degradation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for protein degradation therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The protein degradation therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Bavdegalutamide (ARV - 110); Vepdegestrant (ARV - 471); Other Types
- 2) By Application: Oncology; Neurodegenerative Diseases; Infectious Diseases; Other Applications
- 3) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes
- Subsegment:
- 1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders; Prostate Cancer Therapy
- 2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders; Breast Cancer Therapy
- Companies Mentioned: Relay Therapeutics; Arvinas Holding Company LLC; Kymera Therapeutics; Nurix Therapeutics; Vividion Therapeutics
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Protein Degradation Therapy Market Characteristics
3. Protein Degradation Therapy Market Trends And Strategies
4. Protein Degradation Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Protein Degradation Therapy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Protein Degradation Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Protein Degradation Therapy Market Growth Rate Analysis
- 5.4. Global Protein Degradation Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Protein Degradation Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Protein Degradation Therapy Total Addressable Market (TAM)
6. Protein Degradation Therapy Market Segmentation
- 6.1. Global Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bavdegalutamide (ARV - 110)
- Vepdegestrant (ARV - 471)
- Other Types
- 6.2. Global Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Neurodegenerative Diseases
- Infectious Diseases
- Other Applications
- 6.3. Global Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmaceutical Companies
- Biotechnology Companies
- Academic And Research Institutes
- 6.4. Global Protein Degradation Therapy Market, Sub-Segmentation Of Bavdegalutamide (ARV-110), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Androgen Receptor Degraders
- Prostate Cancer Therapy
- 6.5. Global Protein Degradation Therapy Market, Sub-Segmentation Of Vepdegestrant (ARV-471), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Estrogen Receptor Degraders
- Breast Cancer Therapy
- 6.6. Global Protein Degradation Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Proteolysis-Targeting Chimeras (PROTACs)
- Molecular Glues
- Other Targeted Protein Degradation Platforms
7. Protein Degradation Therapy Market Regional And Country Analysis
- 7.1. Global Protein Degradation Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Protein Degradation Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Protein Degradation Therapy Market
- 8.1. Asia-Pacific Protein Degradation Therapy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Protein Degradation Therapy Market
- 9.1. China Protein Degradation Therapy Market Overview
- 9.2. China Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Protein Degradation Therapy Market
- 10.1. India Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Protein Degradation Therapy Market
- 11.1. Japan Protein Degradation Therapy Market Overview
- 11.2. Japan Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Protein Degradation Therapy Market
- 12.1. Australia Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Protein Degradation Therapy Market
- 13.1. Indonesia Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Protein Degradation Therapy Market
- 14.1. South Korea Protein Degradation Therapy Market Overview
- 14.2. South Korea Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Protein Degradation Therapy Market
- 15.1. Western Europe Protein Degradation Therapy Market Overview
- 15.2. Western Europe Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Protein Degradation Therapy Market
- 16.1. UK Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Protein Degradation Therapy Market
- 17.1. Germany Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Protein Degradation Therapy Market
- 18.1. France Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Protein Degradation Therapy Market
- 19.1. Italy Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Protein Degradation Therapy Market
- 20.1. Spain Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Protein Degradation Therapy Market
- 21.1. Eastern Europe Protein Degradation Therapy Market Overview
- 21.2. Eastern Europe Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Protein Degradation Therapy Market
- 22.1. Russia Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Protein Degradation Therapy Market
- 23.1. North America Protein Degradation Therapy Market Overview
- 23.2. North America Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Protein Degradation Therapy Market
- 24.1. USA Protein Degradation Therapy Market Overview
- 24.2. USA Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Protein Degradation Therapy Market
- 25.1. Canada Protein Degradation Therapy Market Overview
- 25.2. Canada Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Protein Degradation Therapy Market
- 26.1. South America Protein Degradation Therapy Market Overview
- 26.2. South America Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Protein Degradation Therapy Market
- 27.1. Brazil Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Protein Degradation Therapy Market
- 28.1. Middle East Protein Degradation Therapy Market Overview
- 28.2. Middle East Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Protein Degradation Therapy Market
- 29.1. Africa Protein Degradation Therapy Market Overview
- 29.2. Africa Protein Degradation Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Protein Degradation Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Protein Degradation Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Protein Degradation Therapy Market Competitive Landscape And Company Profiles
- 30.1. Protein Degradation Therapy Market Competitive Landscape
- 30.2. Protein Degradation Therapy Market Company Profiles
- 30.2.1. Relay Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Arvinas Holding Company LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Kymera Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Nurix Therapeutics Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Vividion Therapeutics Overview, Products and Services, Strategy and Financial Analysis
31. Protein Degradation Therapy Market Other Major And Innovative Companies
- 31.1. Mission Therapeutics Ltd.
- 31.2. C4 Therapeutics Inc.
- 31.3. Cullgen Inc.
- 31.4. Frontier Medicines
- 31.5. Foghorn Therapeutics
- 31.6. Aileron Therapeutics
- 31.7. Ribometrix Inc.
- 31.8. Nimbus Therapeutics
- 31.9. Jnana Therapeutics
- 31.10. KSQ Therapeutics
- 31.11. Stoke Therapeutics
- 31.12. Flare Therapeutics
- 31.13. Accent Therapeutics
- 31.14. Monte Rosa Therapeutics
- 31.15. Lycia Therapeutics
32. Global Protein Degradation Therapy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Protein Degradation Therapy Market
34. Recent Developments In The Protein Degradation Therapy Market
35. Protein Degradation Therapy Market High Potential Countries, Segments and Strategies
- 35.1 Protein Degradation Therapy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Protein Degradation Therapy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Protein Degradation Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250423_r33533_Protein_Degradation_Therapy_GMR_2025
